The Acoustic Pulse Difference

EKOS Acoustic Pulse Thrombolysis is a minimally invasive system for dissolving thrombus. The ultrasonic core generates a localized acoustic field which greatly accelerates lytic dispersion by driving the drug deeper into the clot and unwinding the fibrin to expose plasminogen receptor sites.

Acoustic Pulse Thrombolysis:
- Speeds time to dissolution
- Lower the risk of bleeding and 48% greater drug absorption within 1 hour
- Reduces dosage requirements by as much as 84% greater drug absorption within 2 hours

More Effective Drug Delivery:
- Reduces dosage requirements by as much as 68% compared to standard CDT
- Requires up to 4x less drug dosage than systemic delivery

Superior Thrombus Clearance:
- 48% greater drug absorption within 1 hour
- 84% greater drug absorption within 2 hours

Treatment for PE, DVT & PAO

Pulmonary Embolism
The EkoSonic Endovascular System is the only endovascular device cleared by the FDA for the treatment of pulmonary embolism. The current standard of care, anti-coagulation, does not resolve existing thrombus. EKOS has been shown to yield safe and effective results for acute, massive and submassive PE. It opens up and restores pulmonary artery pressure while minimizing the risk of bleeding.

The ULTIMA study was a randomized controlled trial of 59 patients comparing heparin plus EKOS therapy (n=30) to heparin alone (n=29) for the treatment of intermediate risk PE.
- EKOS reversed RVD at 24 hours, with a reduction in RV/LV ratio of 23% compared to 3% with heparin alone, using 20 mg tPA over 15min, with a safety profile equivalent to heparin.
- The SEATTLE II study (n=150), using an EKOS combination to evaluate safety and efficacy for massive and intermediate risk PE. It improves right ventricular function and pulmonary artery pressure while minimizing the risk of bleeding.
- Studies with EKOS demonstrate:
  - Higher rates of complete lysis and shorter infusion time compared to traditional CDT
  - Between 35%-68%* reduction in thrombolytic dose compared to traditional CDT depending on thrombolytic drug used
  - Evidence of clearance behind valves and in IVC filters
  - 98% of patients experiencing no DVT complications
  - 90% vessel patency at long term follow up

Deep Vein Thrombosis
The EkoSonic Endovascular System dissolves thrombus more completely even behind valves and IVC filters. It quickly restores blood flow, potentially reducing the risk of pulmonary embolism and post-thrombotic syndrome (PTS), which affects approximately 50% of patients with acute ilio-femoral DVT.

Studies with EKOS demonstrate:
- Higher dissolution rate of entire thrombus (95.3% vs. 66.7%, p<0.002)
- Lower bleeding rates (4.7% vs. 23.8%, p<0.026)
- Lower 30-day amputation rate (19.5% vs. 42.9%, p<0.04)
- Shorter hospital stays (5.7 vs. 8.3 days, p<0.027)

Peripheral Arterial Occlusion
The EkoSonic Endovascular System accelerates drug penetration, even in difficult-to-reach areas.

Compared to traditional CDT EKOS offers:
- Shorter treatment times
- Higher dissolution rate of entire thrombus (95.3% vs. 66.7%, p<0.002)
- Lower bleeding rates (4.7% vs. 23.8%, p<0.026)
- Lower 30-day amputation rate (19.5% vs. 42.9%, p<0.04)
- Shorter hospital stays (5.7 vs. 8.3 days, p<0.027)

The EKOS System’s targeted ultrasound waves accelerate thrombus dissolution by unwinding the fibrin matrix.
“Patients stricken with a life-threatening pulmonary embolism can be successfully and safely treated with EKOS™.”

Samuel Z. Goldhaber, MD.
Professor of Medicine, Harvard Medical School
Director, Thrombosis Research Group, Brigham and Women’s Hospital
The fast, safe solution for vascular thrombosis.

The EkoSonic™ Endovascular System:
- Quality clinical outcomes
- Predictable results
- Minimised bleeding risk
- Efficient procedures

- Reduces Ry/LV ratio by more than 25% on average
- Reduces PA pressures by 26% at 68 hours
- 75% less thrombolytic drug dosage than standard treatment
- Minimised risk of bleeding

- 50% of DVT patients have PE
- Remoist thrombus more completely compared to CDT
- Reduce post thrombotic syndrome

- Lower 30 day amputation rate
- Lower bleeding rate when compared to CDT
- Higher complete dissolution rate of thrombus

The EkoSonic™ Endovascular System

50cm Treatment Zone
500-56150

40cm Treatment Zone
500-56140

30cm Treatment Zone
500-56130

24cm Treatment Zone
500-56124

18cm Treatment Zone
500-56118

12cm Treatment Zone
500-56112

6cm Treatment Zone
500-56106

The EkokSonic™ effect (in green) changes the standard of care for pulmonary embolism and dissolves the thrombus more completely, even in difficult to reach areas for deep vein thrombosis and peripheral arterial occlusion.

EKOS™ Acoustic Pulse Thrombolysis™ accelerates thrombus dissolution.

Contact us:
Address: Lakeview, Riverside Way, Watchmoor Park, Camberley, Surrey GU15 3YL UK
Email: customerservice@ekoscorp.com
Website: www.ekoscorp.com
Online Learning Center: www.ekoscorp.com/learningcenter.htm

INDICATIONS FOR USE:

The EkoSonic™ Endovascular System is intended for controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. The EkoSonic™ Endovascular System is CE Marked for the treatment of pulmonary embolism with a ≥50% clot burden in one or both main pulmonary arteries or lobar pulmonary arteries, and evidence of right heart dysfunction based on right heart pressures (mean pulmonary artery pressure ≥25 mmHg) or echocardiographic evaluation. Contraindications: Not designed for peripheral vasculature dilation purposes. This system is contraindicated when, in the medical judgment of the physician, such a procedure may compromise that patient’s condition. Such conditions include but are not limited to: • Tortuous vascular anatomy compromising safe introduction of endovascular equipment • Conditions associated with increased risk of bleeding. See device instructions for use for complete prescribing information

http://ekoscorp.com/international_enter.htm#Resources

About EKOS™

EKOS Corporation, a BTG International group company, pioneered the development and clinical application of ultrasound infusion technologies in medicine, introducing its first system for the treatment of vascular thrombosis in 2005. Today, interventional radiologists, cardiologists, and cardiothoracic and vascular surgeons at leading institutions around the world use the EKOS™ EkoSonic™ Endovascular System to provide faster, safer and more complete dissolution of thrombus. To find out more about the EKOS™ EkoSonic™ Endovascular System, visit www.ekoscorp.com.

About BTG

BTG is a growing international specialist healthcare company that is developing and commercialising products targeting acute care, cancer and vascular diseases.

The company has diversified revenues from sales of its own marketed products and from royalties on partnered products, and is seeking to acquire new programs and products to develop and market to specialist physicians.

To find out more about the BTG International group companies and our products, visit www.btgplc.com.